#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paraneoplastic neurological syndrome Systemic scleroderma Ehlers-Danlos syndrome Anaplastic large cell lymphoma T- and null-cell types Neonatal asphyxia Neuromyelitis optica spectrum disorder Pericarditis Gastrointestinal disorder Hypomagnesaemia Ocular lymphoma Heavy menstrual bleeding Myelodysplastic syndrome Biliary cancer metastatic Oesophageal squamous cell carcinoma stage III Chorioretinitis More trials…

    Learn about Rare Diseases

    Rhabdoid tumour – Treatment Mucopolysaccharidosis II – Diagnostics Nephrotic syndrome – Treatment Lymphangiosarcoma – Diagnostics MELAS syndrome – Trials in Disease Urea cycle disorder – Trials in Disease Cystic fibrosis lung Haemophilia A with anti factor VIII Lysosomal storage disorder – Diagnostics Primary biliary cholangitis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Db-Oto-5 Ceftriaxone Sodium BROLUCIZUMAB Losmapimod Pentixafor Charcoal, Activated Lixisenatide Siponimod Pimecrolimus L-Threonine Alxn2220 Dinutuximab Beta ADS-019 Triamcinolone Gtaexs617 Ipatasertib Pelareorep Ucp2 Histamine Hydrochloride Esomeprazole Magnesium More therapies…

    Learn about Your Condition

    Testis cancer Angina pectoris Stevens-Johnson syndrome Multiple sclerosis Lip and/or oral cavity cancer Seizure Lupus nephritis Dermatomyositis Oropharyngeal cancer recurrent Pemphigus Inguinal hernia Von Willebrand's disease Small intestine adenocarcinoma Paedophilia Cytomegalovirus infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Migraine

  • Study on the Long-Term Safety of Rimegepant for Treating Acute Migraine in Children and Adolescents Aged 6 to 17 Years

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Poland Spain

  • Study on Rimegepant for Treating Acute Migraine in Children and Adolescents Aged 6 to 17 Years

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Poland Spain Sweden

  • Study on Atorvastatin for Preventing Chronic Migraine in Adults

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Atorvastatin
    • Placebo
    Norway

  • Study on Atorvastatin for Preventing Episodic Migraine in Adults

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Atorvastatin
    • Placebo
    Norway

  • Study on the Safety and Effectiveness of Atogepant for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

    Recruiting

    3 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Atogepant
    Belgium Denmark France Hungary Italy The Netherlands +4

  • Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

    Recruiting

    3 1 1
    Investigated Drugs:
    • Atogepant
    Belgium Denmark France Hungary Italy The Netherlands +5
Previous Page
1 2 3 4 5 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!